Accordingly, synthetic ERα ligands (e.g., fulvestrant [ICI182,780-ICI] and tamoxifen) alter intracellular ERα levels and inhibit E2-dependent breast cancer (BC) cell proliferation [10,12]. Here, ESR1 is linked to breast carcinoma.